Cargando…
Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases
BACKGROUND: Cancer of unknown primary (CUP) accounts for approximately 3% of all malignancies. Despite extensive laboratory and imaging efforts, the primary site usually cannot be unequivocally confirmed, and the treatment for the most part remains empirical. Recently, identification of common cance...
Autores principales: | Gatalica, Zoran, Millis, Sherri Z., Vranic, Semir, Bender, Ryan, Basu, Gargi D., Voss, Andreas, Von Hoff, Daniel D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322997/ https://www.ncbi.nlm.nih.gov/pubmed/25415047 |
Ejemplares similares
-
Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1
por: Gatalica, Zoran, et al.
Publicado: (2015) -
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
por: Vranic, Semir, et al.
Publicado: (2022) -
Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials
por: Friedlander, Michael L., et al.
Publicado: (2016) -
Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
por: Vranic, Semir, et al.
Publicado: (2022) -
PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)